Abstract
Aims To assess parental awareness of respiratory syncytial virus (RSV) and the level of acceptance of future RSV prevention strategies.
Methods A cross-sectional online survey was implemented targeting “future” and “current” parents of children aged ≤5 years in Australia.
Results From 1,992 eligible participants, two non-mutually exclusive subgroups were formed; “current” parents (N=1931) and “pregnant/planning” parents (N=464; 403 also “current” parents; 61 “future” parents). Participants were predominantly (86.6%) aged 25-39 years and 68.5% with university education. The majority (89.6% current; 78.7% future) had heard of RSV. Of those, 64.2% (current) and 50.0% (future) were aware that pneumonia is associated with RSV; 71.8% (current) and 52.1% (future) were aware that bronchiolitis is associated. In multivariable logistic regression analyses, Australian-born parents (aOR=2.47 [95%CI:1.48-4.12]), living in the Eastern States (e.g., New South Wales: aOR=6.15 [95%CI:2.10-18.04]), with a university level education (aOR=2.61 [95%CI:1.38-4.94]) and being a current parent (aOR=12.26 [95%CI:2.82-53.28]) were associated with higher RSV awareness. There was a high level of acceptance for maternal vaccines (future: 79.3%) and infant immunisation (all: 81.7%).
Conclusion While RSV awareness and immunisation acceptance was high, there was limited knowledge of severity of RSV, especially in future parents. Education campaigns need to be developed to increase RSV knowledge.
Key notes The success of RSV immunisation programs is dependent on the community having sufficient disease awareness and acceptance of new immunisation strategies. Majority of parents in the study had heard of RSV, however lacked awareness on associated conditions and disease severity, particularly future parents. Education and awareness campaigns are required to inform parents about RSV and future immunisations; there is a critical opportunity to increase awareness prior to immunisation arrival.
Competing Interest Statement
Professor Richmond and Associate Professor Moore is in receipt of research funds from Merck Sharp & Dohme (Australia) Pty Ltd and Sanofi-Aventis Australia Pty Ltd (unrelated to the work presented in this paper). Professor Richmond and Associate Professor Moore has also received institutional honoraria for participating in advisory committees (Pfizer, Merck Sharp & Dohme, EvoHealth) also unrelated to the work presented in this paper.
Funding Statement
This study was funded through a Wesfarmers Centre of Vaccine and Infectious Diseases Seed Grant at the Telethon Kids Institute. HCM is funded by a Stan Perron Charitable Foundation Fellowship and a Future Health Research and Innovation Fund through the WA Near-miss Awards program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained by the University of Western Australia Human Research Ethics Committee (ET000182).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw data produced in the present study is not available. However, aggregated data is available on request.
